Search Results | MSF Science Portal

Journal Article

|

Research

Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, et al.

2023-12-01 • Lancet Microbe

BACKGROUND
Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up. People at risk of weak tuberculosis drug regimens are a priority for novel drug access despite t...

Journal Article

|

Research

Goig GA, Menardo F, Salaam-Dreyer Z, Dippenaar A, Streicher EM, et al.

2023-06-06 • Lancet Microbe

BACKGROUND
Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitnes...

Journal Article

|

Research

Apolisi I, Cox HS, Tyeku N, Daniels J, Mathee S, et al.

2023-02-21 • Open Forum Infectious Diseases

BACKGROUND
Children and adolescents with household exposure to multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) are at high risk of developing TB disease. Tuberculosis pre...

Journal Article

|

Letter

Memani B, Furin J, Cox HS, Reuter A

2022-12-01 • International Journal of Tuberculosis and Lung Disease

Journal Article

|

Letter

Furin J, Reuter A, Eyde L, Cox HS

2022-11-01 • International Journal of Tuberculosis and Lung Disease

Journal Article

|

Letter

Tyeku N, Apolisi I, Daniels J, Beko B, Memani B, et al.

2022-10-01 • International Journal of Tuberculosis and Lung Disease

Journal Article

|

Review

Fargher J, Reuter A, Furin J

2019-01-01 • Current Opinion in HIV and AIDS

PURPOSE OF REVIEW
More than two billion people are infected with Mycobacterium tuberculosis and few of them are ever offered therapy in spite of such treatment being associated with ...

Journal Article

|

Case Report/Series

de Vos M, Ley SD, Wiggins KB, Derendinger B, Dippenaar A, et al.

2019-05-30 • New England Journal of Medicine

Journal Article

|

Research

Ndjeka N, Campbell JR, Meintjes GA, Maartens G, Schaaf HS, et al.

2022-05-02 • Lancet Infectious Diseases

BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...

Journal Article

|

Short Report

Reuter A, Hughes J, Furin J

2019-09-14 • Lancet

Children bear a substantial burden of suffering when it comes to tuberculosis. Ironically, they are often left out of the scientific and public health advances that have led to important...

Journal Article

|

Research

Ismail N, Omar SV, Moultrie H, Bhyat Z, Conradie F, et al.

2021-11-12 • Lancet Infectious Diseases

BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...

Journal Article

|

Commentary

Reuter A, Furin J

2018-09-08 • Lancet HIV

Journal Article

|

Commentary

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S, et al.

2020-11-01 • International Journal of Tuberculosis and Lung Disease

Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...

Journal Article

|

Research

Reuter A, Tisile P, von Delft D, Cox HS, Cox V, et al.

2017-11-01 • International Journal of Tuberculosis and Lung Disease

For decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited...

Journal Article

|

Research

Cox HS, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F, et al.

2021-11-01 • Lancet Microbe

BACKGROUND
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...

Journal Article

|

Research

Mohr-Holland E, Daniels J, Reuter A, Rodriguez CA, Mitnick CD, et al.

2022-02-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...

Journal Article

|

Case Report/Series

Mohr-Holland E, Daniels J, Furin J, Loveday M, Mudaly V, et al.

2021-05-01 • Pediatric Infectious Disease Journal

This brief report presents a series of 5 pregnant women treated for rifampicin-resistant tuberculosis with the novel drugs bedaquiline, delamanid, and linezolid as part of an optimized b...

Journal Article

|

Research

Reuter A, Beko B, Memani B, Furin J, Daniels J, et al.

2022-01-31 • Tropical Medicine and Infectious Disease

Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outcomes. In 2017, a SBIRT (SU screening-brief intervention-referral to treatment) was inte...

Journal Article

|

Commentary

Loveday M, Reuter A, Furin J, Seddon JA, Cox HS

2019-03-22 • Lancet Infectious Diseases

Final results of the STREAM trial were presented at the 2018, 49th Union World Conference on Lung Health, held in The Hague, The Netherlands. STREAM is a randomised controlled trial comp...

Journal Article

|

Research

Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M, et al.

2020-10-01 • International Journal of Tuberculosis and Lung Disease

Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...

Science Portal

Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study

Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study

Tuberculosis diagnosis and preventive monotherapy among children and adolescents exposed to rifampicin-resistant tuberculosis in the household

A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB

A test of infection should not be a “standard” for guiding TB preventive therapy in at-risk populations

Pediatric delamanid treatment for children with rifampicin-resistant TB

Demanding an end to tuberculosis: treatment of tuberculosis infection among persons living with and without HIV

Bedaquiline microheteroresistance after cessation of tuberculosis treatment

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa a retrospective cohort study

Challenges and controversies in childhood tuberculosis

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Reducing harm in the treatment of multidrug-resistant tuberculosis

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study

Early mortality during rifampicin-resistant TB treatment

Outcomes of children born to pregnant women with drug-resistant tuberculosis treated with novel drugs in Khayelitsha, South Africa: a report of five patients

Implementing a substance-use screening and intervention program for people living with rifampicin-resistant tuberculosis: pragmatic experience from Khayelitsha, South Africa

The STREAM trial: missed opportunities and lessons for future clinical trials

Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?